Compare Merck & Co., Inc. (MRK) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: Merck & Co., Inc. is far larger — about 3718.8× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| MRK | MSTZ | |
|---|---|---|
Market Cap | $351.28B | $94.46M |
Volume | 7,969,665 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $27.92 |
52-Week Low | $82.49 | $2.29 |
Typical Hold Time | 98 Days | 8 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
MSTZ trades at $2.73, up 2.63% today, but technical indicators show a bearish trend with moving averages signaling caution. The stock lacks available fundamental data for key valuation and profitability metrics, making financial health assessment challenging. Recent ETF performance coverage highlights market volatility but provides no direct company-specific news.
The outlook is clouded by missing financials and bearish technicals. Investment opportunity hinges on future earnings visibility and competitive positioning. Key risks include potential weak fundamentals, market volatility, and lack of analyst coverage, requiring careful due diligence before consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
